There is high feasibility of translating anti-survivin therapy to breast cancer, as it has already been pursued as a cancer therapeutic target by various strategies [27, 45–47], and is already measured in the clinic on the validated prognostic assays, Prosigna [19] and Oncotype DX [18]. Here, BIRC5 is linked to breast cancer.